Table 2. Demographics of patients initiated on etanercept, adalimumab, and infliximab, 2010–2011.
| Etanercept | Adalimumab | Infliximab | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | 37 | 38 | 17 | |||||||
| Variable | Mean | SD | Median | Mean | SD | Median | Mean | SD | Median | P-value |
| Age (years) | 52.92 | 15.15 | 56.0 | 49.47 | 15.97 | 55.0 | 44.60 | 17.69 | 41.0 | 0.141 |
| Body mass index (kg/m2) | 30.44 | 6.02 | 30.2 | 28.30 | 4.92 | 28.5 | 27.02 | 4.79 | 26.7 | 0.108 |
| Aspartate aminotransferase (mg/dL) | 28.57 | 28.06 | 22.0 | 24.00 | 13.43 | 21.0 | 18.31 | 6.02 | 18.0 | 0.122 |
| Alanine aminotransferase (mg/dL) | 33.59 | 34.75 | 24.0 | 27.92 | 17.59 | 230 | 16.00 | 5.29 | 15.0 | 0.004 |
Notes.
- GI
- gastrointestinal
- CD
- Crohn’s disease
- MI
- myocardial infarction
- RF
- rheumatoid factor
- TB
- tuberculosis
- HBsAg
- hepatitis B surface antigen
- HBsAb
- hepatitis B surface antibody
- HCAb
- hepatitis C antibody
*
“Other” includes ulcerative colitis (N = 5), uveitis (N = 1), and spondylarthropathy (N = 1).